Skip to main content
Premium Trial:

Request an Annual Quote

OriGene, Cytomyx Partner on Gene Expression Biomarker Validation

NEW YORK, Oct. 17 (GenomeWeb News) - OriGene Technologies and Cytomyx Holdings have signed an agreement to co-develop tools to profile gene expression and validate biomarkers in human cancers, the companies said today.

 

Under the terms of the agreement, Cytomyx will supply hundreds of characterized RNA samples from several major cancers. OriGene will use these samples to update its Rapid-Scan Gene Expression Panel product line, which will enable researchers to determine linkages between gene expression and tumor occurrence and development, the companies said.

 

Cytomyx will also develop tissue microarrays to further investigate these linkages at the protein expression level using immunohistochemistry.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.